FORMULATION AND EVALUATION OF MICROSPHERES CONTAINING LOSARTAN POTASSIUM BY SPRAY-DRYING TECHNIQUE

被引:0
作者
Balwierz, Radoslaw [1 ]
Jankowski, Andrzej [1 ]
Jasinska, Agata [2 ]
Marciniak, Dominik [3 ]
Pluta, Janusz [3 ]
机构
[1] Med Univ Silesia, Dept Appl Pharm, Inst Pharmaceut Technol, 3 Kasztanowa St, PL-41200 Sosnowiec, Poland
[2] City Hosp Chorzow, Dept Internal Med, 11 Strzelcow Bytomskich St, PL-41500 Chorzow, Poland
[3] Wroclaw Med Univ, Dept & Inst Pharmaceut Technol, 211 Borowska St, PL-50556 Wroclaw, Poland
来源
ACTA POLONIAE PHARMACEUTICA | 2016年 / 73卷 / 05期
关键词
losartan potassium; microspheres; spray drying; Eudragit L30D55; kinetics; EUDRAGIT MICROPARTICLES; DELIVERY; RELEASE; MICROENCAPSULATION; PARAMETERS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite numerous applications of microspheres, few works devoted to the preparation of microspheres containing cardiac medications have been published. This study presents the potential of receiving microspheres containing losartan potassium, based on a matrix containing Eudragit L30D55. The study focuses on the possibilities of controlled release of losartan potassium from microspheres in order to reduce the dosage frequency, and also provides information on the effect of the addition of excipients to the quality of the microspheres. Microspheres are monolithic, porous or smooth microparticles ranging from 1 to 500 microns in size. For the preparation of microspheres containing losartan potassium, the spray-drying method was used. The performed study confirmed that the spray-drying technology used to obtain microspheres meets the criteria of size and morphology of the microparticles. The assessment of the kinetics of losartan potassium release from the examined microspheres demonstrated that the release profile followed the first- and/or zero-order kinetics. The use of spray-drying techniques as well as Eudragit L30D55 polymer matrix to obtain the microspheres containing losartan potassium makes it possible to obtain a product with the required particle morphology and particle size ensuring the release of the active substance up to 12 h.
引用
收藏
页码:1275 / 1286
页数:12
相关论文
共 38 条
  • [21] Pattabhi K., 2004, BIOL PHARM BULL, V27, P1717
  • [22] Microspheres in cancer therapy
    Rajput, M. S.
    Agrawal, P.
    [J]. INDIAN JOURNAL OF CANCER, 2010, 47 (04) : 458 - 468
  • [23] Biodegradable anionic acrylic resin based hollow microspheres of moderately water soluble drug Rosiglitazone Maleate: preparation and in vitro characterization
    Rane, B. R.
    Gujarathi, N. A.
    Patel, J. K.
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2012, 38 (12) : 1460 - 1469
  • [24] Albumin Microspheres as an Ocular Delivery System for Pilocarpine Nitrate
    Rathod, Sudha
    Deshpande, S. G.
    [J]. INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 70 (02) : 193 - 197
  • [25] Production of pH-Responsive Microparticles by Spray Drying: Investigation of Experimental Parameter Effects on Morphological and Release Properties
    Rizi, Khalida
    Green, Rebecca J.
    Donaldson, Michael
    Williams, Adrian C.
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (02) : 566 - 579
  • [26] Moisture plasticization for enteric Eudragit® L30D-55-coated pellets prior to compression into tablets
    Rujivipat, Soravoot
    Bodmeier, Roland
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2012, 81 (01) : 223 - 229
  • [27] Sam MT, 2008, INTERNET J PHARM, V6, P1
  • [28] SAWICKI W, 2009, FARM POL, V65, P311
  • [29] Shanmugam S., 2011, INT J PHARM TECH RES, V3, P526
  • [30] Clinical pharmacokinetics of Losartan
    Sica, DA
    Gehr, TWB
    Ghosh, S
    [J]. CLINICAL PHARMACOKINETICS, 2005, 44 (08) : 797 - 814